NMT1 and hematopoietic and lymphoid cell neoplasm: After describing the absence of NMT2 in most hematologic cancer cell lines and tumors, and their high sensitivity towards PCLX-001, we hypothesized that NMTI could exploit this loss by targeting the remaining NMT1 in an approach reminiscent of synthetic lethality [24].